Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan children

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3018-3030

  Tumwebaze, Patrick ^a   Conrad, Melissa D ^b   Walakira, Andrew ^a   LeClair, Norbert ^b   Byaruhanga, Oswald ^a   Nakazibwe, Christine ^a   Kozak, Benjamin ^b   Bloome, Jessica ^b   Okiring, Jaffer ^a   Kakuru, Abel ^a   Bigira, Victor ^a   Kapisi, James ^a   Legac, Jennifer ^b   Gut, Jiri ^b   Cooper, Roland A ^c   Kamya, Moses R ^d   Havlir, Diane V ^b   Dorsey, Grant ^b   Greenhouse, Bryan ^b   Nsobya, Samuel L ^a   Rosenthal, Philip J ^b   more..

^a INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DOMINICAN UNIVERSITY OF CALIFORNIA   (United States)

^d MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; CHLOROQUINE; COTRIMOXAZOLE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; PIPERAQUINE; QUININE; AMODIAQUINE; ARTEMISININ DERIVATIVE; CARRIER PROTEIN; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN; QUINOLINE DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC50; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RECURRENT INFECTION; UGANDA; UGANDAN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG SENSITIVITY; GENETIC POLYMORPHISM; GENETICS; INFANT; PRESCHOOL CHILD;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; CHLOROQUINE; CLINICAL TRIALS AS TOPIC; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; QUININE; QUINOLINES; UGANDA;

EID: 84939820804     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05141-14     Document Type: Article

References (74)

1. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. Lancet 383:723-735. http://dx.doi.org/10.1016/S0140-6736(13)60024-0.
2. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsobya S, Staedke SG, Donnelly MJ, Wabwire-Mangen F, Talisuna A, Dorsey G, Kamya MR, Rosenthal PJ. 2012. Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 121:184-195. http://dx.doi.org/10.1016/j.actatropica.2011.03.004.
3. Rosenthal PJ. 2013. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol 89:1025-1038. http://dx.doi.org/10.1111/mmi.12349.
4. Nosten F, White NJ. 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77(6 Suppl):181-192.
5. Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7:864-874. http://dx.doi.org/10.1038/nrmicro2239.
6. World Health Organization. 2010. Guidelines for the treatment of malaria. Second edition. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf?ua-1.
7. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H. 2008. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3:e2390. http://dx.doi.org/10.1371/journal.pone.0002390.
8. President's Malaria Initiative. 2010. President's Malaria Initiative Uganda malaria operational plan for FY 2010. President's Malaria Initiative. United States Agency for International Development, Washington, DC. http://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy10/uganda-mop-fy10.pdf?sfvrsn-6.
9. ter Kuile FO, van Eijk AM, Filler SJ. 2007. Effect of sulfadoxinepyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297:2603-2616. http://dx.doi.org/10.1001/jama.297.23.2603.
10. Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. 2011. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 8:e1000408. http://dx.doi.org/10.1371/journal.pmed.1000408.
11. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. 2014. Protective efficacy and safety of three anti-malarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689. http://dx.doi.org/10.1371/journal.pmed.1001689.
12. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58:1404-1412. http://dx.doi.org/10.1093/cid/ciu150.
13. Ecker A, Lehane AM, Clain J, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol 28:504-514. http://dx.doi.org/10.1016/j.pt.2012.08.002.
14. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. 2007. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 51:3023-3025. http://dx.doi.org/10.1128/AAC.00012-07.
15. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL. 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 51:991-997. http://dx.doi.org/10.1128/AAC.00875-06.
16. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87. http://dx.doi.org/10.2165/00003495-200565010-00004.
17. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouédraogo JB, Rosenthal PJ. 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 54:1949-1954. http://dx.doi.org/10.1128/AAC.01413-09.
18. Some AF, Zongo I, Compaoré YD, Sakandé S, Nosten F, Ouédraogo JB, Rosenthal PJ. 2014. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58:3660-3665. http://dx.doi.org/10.1128/AAC.02406-14.
19. Conrad MD, Le Clair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisininbased combination therapies on Plasmodium falciparum polymorphisms that modulated drug sensitivity in Ugandan children. J Infect Dis 210: 344-353. http://dx.doi.org/10.1093/infdis/jiu141.
20. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014-1017. http://dx.doi.org/10.1086/427997.
21. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, Rosenthal PJ, Ouedraogo JB. 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369:491-498. http://dx.doi.org/10.1016/S0140-6736(07)60236-0.
22. Baliraine FN, Rosenthal PJ. 2011. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis 204:1120-1124. http://dx.doi.org/10.1093/infdis/jir486.
23. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
24. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
25. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D. 2013. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 57:914-923. http://dx.doi.org/10.1128/AAC.01868-12.
26. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. http://dx.doi.org/10.1038/nature12876.
27. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, Arinaitwe E, Tappero JW, Kaharuza F, Kamya MR, Dorsey G. 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 13:32. http://dx.doi.org/10.1186/1475-2875-13-32.
28. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, Dorsey G, Rosenthal PJ. 2014. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One 9:e105690. http://dx.doi.org/10.1371/journal.pone.0105690.
29. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411-423. http://dx.doi.org/10.1056/NEJMoa1314981.
30. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, Arinaitwe E, Kamya M, Tappero J, Staedke SG, Dorsey G, Greenhouse B, Rosenthal PJ. 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 91:54-61. http://dx.doi.org/10.4269/ajtmh.13-0647.
31. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. 2010. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 54:1200-1206. http://dx.doi.org/10.1128/AAC.01412-09.
32. Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, Kamya MR, Staedke SG, Donnelly MJ, Drakeley C, Greenhouse B, Dorsey G, Lindsay SW. 2014. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J 13:111. http://dx.doi.org/10.1186/1475-2875-13-111.
33. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. 2012. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 367:2110-2118. http://dx.doi.org/10.1056/NEJMoa1200501.
34. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. 2005. Simple histidine-rich protein 2 double-site sandwich enzymelinked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother 49:3575-3577. http://dx.doi.org/10.1128/AAC.49.8.3575-3577.2005.
35. Basco L. 2007. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2007/9 789241595155-eng.pdf?ua-1.
36. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52:565-568.
37. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257-263. http://dx.doi.org/10.1056/NEJM200101253440403.
38. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 108:13-23. http://dx.doi.org/10.1016/S0166-6851(00)00201-2.
39. Leclair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SL, Rosenthal PJ. 2013. Optimization of a ligase detection reaction fluorescent microsphere assay for the characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. J Clin Microbiol 51:2564-2570. http://dx.doi.org/10.1128/JCM.00904-13.
40. Ringwald P, Bickii J, Basco LK. 1996. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 55:254-258.
41. Kaddouri H, Djimde A, Dama S, Kodio A, Tekete M, Hubert V, Kone A, Maiga H, Yattara O, Fofana B, Sidibe B, Sangare CP, Doumbo O, Le Bras J. 2008. Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol 38:791-798. http://dx.doi.org/10.1016/j.ijpara.2007.12.002.
42. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, Juma D, Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters NC, Walsh DS, Johnson JD. 2013. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011. PLoS One 8:e64299. http://dx.doi.org/10.1371/journal.pone.0064299.
43. Dahlström S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Martensson A, Farnert A, Sisowath C, Osorio L, Darban H, Andersson B, Kaneko A, Conseil G, Björkman A, Gil JP. 2009. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 200:1456-1464. http://dx.doi.org/10.1086/606009.
44. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. 2001. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 183:1417-1420. http://dx.doi.org/10.1086/319865.
45. Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R, Dokomajilar C, Rosenthal PJ, Dorsey G. 2006. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193:978-986. http://dx.doi.org/10.1086/500951.
46. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, Su XZ. 2002. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418:320-323. http://dx.doi.org/10.1038/nature00813.
47. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, Ruel T, Kateera F, Meya DN, Havlir D, Rosenthal PJ, Dorsey G. 2010. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIVinfected Ugandan children living in an area of widespread antifolate resistance. Malar J 9:177. http://dx.doi.org/10.1186/1475-2875-9-177.
48. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Bjorkman A, Martensson A. 2013. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J 12:103. http://dx.doi.org/10.1186/1475-2875-12-103.
49. Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, Onwona CO, Narh CA, Quashie NB, Abuaku B, Duplessis C, Kronmann KC, Koram KA. 2013. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar J 12:377. http://dx.doi.org/10.1186/1475-2875-12-377.
50. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A. 2009. In vitro activity of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in Pfcrt and Pfmdr1. Antimicrob Agents Chemother 53:5069-5073. http://dx.doi.org/10.1128/AAC.00638-09.
51. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV. 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187:1870-1875. http://dx.doi.org/10.1086/375419.
52. Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe CV. 2014. Return of Widespread Chloroquine-Sensitive Plasmodium falciparum to Malawi. J Infect Dis 210:1110-1114. http://dx.doi.org/10.1093/infdis/jiu216.
53. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355:1959-1966. http://dx.doi.org/10.1056/NEJMoa062032.
54. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ. 2005. Amodiaquine alone, amodiaquine-sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365:1474-1480. http://dx.doi.org/10.1016/S0140-6736(05)66417-3.
55. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. 2006. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 1:e7. http://dx.doi.org/10.1371/journal.pctr.0010007.
56. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ. 2007. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297:2210-2219. http://dx.doi.org/10.1001/jama.297.20.2210.
57. Espié E, Lima A, Atua B, Dhorda M, Flevaud L, Sompwe EM, Palma Urrutia PP, Guerin PJ. 2012. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar J 11:174. http://dx.doi.org/10.1186/1475-2875-11-174.
58. Faye B, Kuete T, Kiki-Barro CP, Tine RC, Nkoa T, Ndiaye JL, Kakpo CA, Sylla K, El Menan H, Gaye O, Faye O, Same-Ekobo A, Moussa K. 2012. Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J 11:433. http://dx.doi.org/10.1186/1475-2875-11-433.
59. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Dhorda M, Boum Y, Jr, Sundaygar T, Zolia YM, Jones JJ, Comte E, Houze P, Jullien V, Carn G, Kiechel JR, Ashley EA, Guerin PJ. 2013. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixeddose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malar J 12:251. http://dx.doi.org/10.1186/1475-2875-12-251.
60. Djallé D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. 2014. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J 13:9. http://dx.doi.org/10.1186/1475-2875-13-9.
61. Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A, Kpoda H, Sorgho H, Ouedraogo JB, Guiguemde TR, D'Alessandro U. 2014. Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Trop Med Int Health 19:469-475. http://dx.doi.org/10.1111/tmi.12274.
62. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G. 2007. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2:e20. http://dx.doi.org/10.1371/journal.pctr.0020020.
63. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB. 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45:1453-1461. http://dx.doi.org/10.1086/522985.
64. Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, Kariuki S, Kachur SP, Slutsker L, Desai M. 2013. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malar J 12:254. http://dx.doi.org/10.1186/1475-2875-12-254.
65. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, Obonyo C, Otieno L, Eyase F, Johnson JD, Omollo R, Perkins DJ, Akhwale W, Juma E. 2014. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J 13:33. http://dx.doi.org/10.1186/1475-2875-13-33.
66. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, Rosenthal PJ, Kamya MR, Tappero JW, Dorsey G. 2014. Longitudinal outcomes in a cohort of Ugandan children randomized to arte-mether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 59:509-516. http://dx.doi.org/10.1093/cid/ciu353.
67. Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, Stokes-Riner A, Taylor TE, Plowe CV. 2012. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS One 7:e42284. http://dx.doi.org/10.1371/journal.pone.0042284.
68. Fall B, Pascual A, Sarr FD, Wurtz N, Richard V, Baret E, Dieme Y, Briolant S, Bercion R, Wade B, Tall A, Pradines B. 2013. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J 12:107. http://dx.doi.org/10.1186/1475-2875-12-107.
69. Issaka M, Salissou A, Arzika I, Guillebaud J, Maazou A, Specht S, Zamanka H, Fandeur T. 2013. Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger. Antimicrob Agents Chemother 57:3415-3419. http://dx.doi.org/10.1128/AAC.02383-12.
70. Tinto H, Bonkian LN, Nana LA, Yerbanga I, Lingani M, Kazienga A, Valea I, Sorgho H, Kpoda H, Guiguemde TR, Ouedraogo JB, Mens PF, Schallig H, D'Alessandro U. 2014. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malar J 13:207. http://dx.doi.org/10.1186/1475-2875-13-207.
71. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ. 2009. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J Infect Dis 200: 1650-1657. http://dx.doi.org/10.1086/647988.
72. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P. 2013. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57:818-826. http://dx.doi.org/10.1128/AAC.00686-12.
73. Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology, Entomology, and Malaria Control (CNM), Royal Cambodian Armed Forces. 2014. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 371:484-485. http://dx.doi.org/10.1056/NEJMc1403007.
74. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909. http://dx.doi.org/10.1038/35002615.